<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077995</url>
  </required_header>
  <id_info>
    <org_study_id>VAPO-UH</org_study_id>
    <nct_id>NCT05077995</nct_id>
  </id_info>
  <brief_title>Validity and Reliability of the Polar M200 Activity Monitor</brief_title>
  <acronym>VAPO</acronym>
  <official_title>Validity and Reliability of the Polar M200 Activity Monitor to Measure Sedentary and Active Time.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study will be to investigate the validity of a consumer available activity&#xD;
      tracker (Polar M200) in free-living conditions to measure sedentary time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to evaluate the validity from a commercially available&#xD;
      wearable Polar device. Consumer-based activity trackers are generally cheaper, designed for&#xD;
      long-term wear and are less intrusive. Potentially, consumer-based activity trackers can be&#xD;
      used for research purposes, but high-quality validation studies are needed. The aims of this&#xD;
      study will be to assess validity of sedentary outcome measures of a Polar device during&#xD;
      free-living conditions in comparison with the ActivPAL3TM activity monitor (AP; PAL&#xD;
      Technologies Ltd, Glasgow, UK), which is considered the gold standard to measure sedentary&#xD;
      time in free-living conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sedentary time</measure>
    <time_frame>7 days</time_frame>
    <description>Sedentary time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steps</measure>
    <time_frame>7 days</time_frame>
    <description>Number of steps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeping time</measure>
    <time_frame>7 days</time_frame>
    <description>Sleeping time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing time</measure>
    <time_frame>7 days</time_frame>
    <description>Standing time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking time</measure>
    <time_frame>7 days</time_frame>
    <description>Walking and running time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Persons</condition>
  <condition>Fitness Trackers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixty healthy adults, aged 18-65 years, will be included following written informed consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polar M200</intervention_name>
    <description>Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  /&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert Op 't Eijnde, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bert Op 't Eijnde, Prof. dr.</last_name>
    <phone>003211292121</phone>
    <email>bert.opteijnde@uhasselt.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ine Nieste, M.Sc</last_name>
    <phone>003211 26 93 50</phone>
    <email>ine.nieste@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hasselt University</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Op Op 't Eijnde, Prof. dr.</last_name>
      <phone>003211292121</phone>
      <email>bert.opteijnde@uhasselt.be</email>
    </contact>
    <investigator>
      <last_name>Ine Nieste, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Bert Op't Eijnde</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

